[go: up one dir, main page]

SE9501067D0 - New peptides - Google Patents

New peptides

Info

Publication number
SE9501067D0
SE9501067D0 SE9501067A SE9501067A SE9501067D0 SE 9501067 D0 SE9501067 D0 SE 9501067D0 SE 9501067 A SE9501067 A SE 9501067A SE 9501067 A SE9501067 A SE 9501067A SE 9501067 D0 SE9501067 D0 SE 9501067D0
Authority
SE
Sweden
Prior art keywords
peptides
new peptides
absorbable
immune response
therapeutic effect
Prior art date
Application number
SE9501067A
Other languages
English (en)
Swedish (sv)
Inventor
Nils Tomas Maarten Eriksson
Sten Haakan Axel Ma Bergstrand
Leif Magnus Lindvall
Bengt Olof Saernstrand
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9501067A priority Critical patent/SE9501067D0/xx
Publication of SE9501067D0 publication Critical patent/SE9501067D0/xx
Priority to PCT/SE1996/000365 priority patent/WO1996030397A1/en
Priority to CZ963440A priority patent/CZ344096A3/cs
Priority to BR9605890A priority patent/BR9605890A/pt
Priority to IL11761596A priority patent/IL117615A0/xx
Priority to SK1501-96A priority patent/SK150196A3/sk
Priority to PL96317348A priority patent/PL317348A1/xx
Priority to JP8529255A priority patent/JPH10501003A/ja
Priority to HU9603537A priority patent/HUP9603537A3/hu
Priority to NZ304468A priority patent/NZ304468A/xx
Priority to AU51662/96A priority patent/AU5166296A/en
Priority to EE9600208A priority patent/EE9600208A/xx
Priority to TR96/00932T priority patent/TR199600932T1/xx
Priority to ZA962345A priority patent/ZA962345B/xx
Priority to EP96908425A priority patent/EP0785945A1/en
Priority to CA002189656A priority patent/CA2189656A1/en
Priority to US08/750,142 priority patent/US6228373B1/en
Priority to ARP960101906A priority patent/AR002724A1/es
Priority to IS4382A priority patent/IS4382A/is
Priority to NO964959A priority patent/NO964959D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SE9501067A 1995-03-24 1995-03-24 New peptides SE9501067D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE9501067A SE9501067D0 (sv) 1995-03-24 1995-03-24 New peptides
US08/750,142 US6228373B1 (en) 1995-03-24 1996-03-22 Peptides with immunomodulatory effects
HU9603537A HUP9603537A3 (en) 1995-03-24 1996-03-22 Peptides having immunmodulator influences
AU51662/96A AU5166296A (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
BR9605890A BR9605890A (pt) 1995-03-24 1996-03-22 Peptido fisiologicamente ativo purificado peptídeo em forma dimérica sais de adição de ácido de peptídeo sais de base de peptídeos formas de dosagem oral intra-traqueal e nasal formulação farmacêutica processos para a preparação da mesma para induzir uma resposta imunomodulatória em um mamifero e para fabricar um peptídeo
IL11761596A IL117615A0 (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
SK1501-96A SK150196A3 (en) 1995-03-24 1996-03-22 Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
PL96317348A PL317348A1 (en) 1995-03-24 1996-03-22 Novel peptides exhibiting immunomodulatory properties
JP8529255A JPH10501003A (ja) 1995-03-24 1996-03-22 免疫調節作用を有する新規ペプチド
PCT/SE1996/000365 WO1996030397A1 (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
NZ304468A NZ304468A (en) 1995-03-24 1996-03-22 Peptide dimers comprising a first and second peptide monomers with each monomer comprising two cysteine amino residues that are aligned contiguous to each other, being absorbable by the epithelial cell lining in mammals compositions
CZ963440A CZ344096A3 (en) 1995-03-24 1996-03-22 Peptides exhibiting immunomodulating effects, pharmaceutical formulations in which such peptides are comprised and their use
EE9600208A EE9600208A (et) 1995-03-24 1996-03-22 Uued immuunomodulatoorse toimega peptiidid
TR96/00932T TR199600932T1 (tr) 1995-03-24 1996-03-22 Yeni peptidlerin bagisiklik düzenleyici (immünomodülatör)etkileri.
ZA962345A ZA962345B (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
EP96908425A EP0785945A1 (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
CA002189656A CA2189656A1 (en) 1995-03-24 1996-03-22 New peptides with immunomodulatory effects
ARP960101906A AR002724A1 (es) 1995-03-24 1996-03-25 Peptido purificado fisiologicamente activo, sales de adicion de acido y sales de bases de dicho peptido, formas de dosificacion oral, intra-traqueal ynasal que comprenden a dicho peptido, formulacion farmaceutica que comprende a dicho peptido, usos de dicho peptido, metodo para la preparacion de dicha
IS4382A IS4382A (is) 1995-03-24 1996-11-08 Ný peptíð með ónæmisbreytandi áhrif
NO964959A NO964959D0 (no) 1995-03-24 1996-11-21 Nye peptider med immunmodulerende virkninger

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501067A SE9501067D0 (sv) 1995-03-24 1995-03-24 New peptides

Publications (1)

Publication Number Publication Date
SE9501067D0 true SE9501067D0 (sv) 1995-03-24

Family

ID=20397676

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501067A SE9501067D0 (sv) 1995-03-24 1995-03-24 New peptides

Country Status (20)

Country Link
US (1) US6228373B1 (xx)
EP (1) EP0785945A1 (xx)
JP (1) JPH10501003A (xx)
AR (1) AR002724A1 (xx)
AU (1) AU5166296A (xx)
BR (1) BR9605890A (xx)
CA (1) CA2189656A1 (xx)
CZ (1) CZ344096A3 (xx)
EE (1) EE9600208A (xx)
HU (1) HUP9603537A3 (xx)
IL (1) IL117615A0 (xx)
IS (1) IS4382A (xx)
NO (1) NO964959D0 (xx)
NZ (1) NZ304468A (xx)
PL (1) PL317348A1 (xx)
SE (1) SE9501067D0 (xx)
SK (1) SK150196A3 (xx)
TR (1) TR199600932T1 (xx)
WO (1) WO1996030397A1 (xx)
ZA (1) ZA962345B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250707A1 (en) * 1996-04-12 1997-10-23 Astra Aktiebolag Cysteine-containing or methionine-containing peptides with immunomodulatory effects
SE9603465D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
WO1999019347A1 (en) * 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
DE59907233D1 (de) * 1998-12-21 2003-11-06 Ivf Hartmann Ag Neuhausen Am R Infektionsschutz-tampon
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
FR2872042B1 (fr) * 2004-06-29 2006-09-15 Soc Extraction Principes Actif Utilisation d'un dipeptide dimerise en tant qu'agent actif dans ou pour la preparation une composition cosmetique et/ou dermatologique
GB2442408B (en) 2005-04-25 2010-06-30 Cadila Pharmaceuticals Ltd Mycobacterium W as an adjuvant
GB0524884D0 (en) 2005-12-06 2006-01-11 Syngenta Ltd Improvements in or relating to organic compounds
KR20140001257A (ko) 2008-05-13 2014-01-06 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0300031A4 (en) 1987-01-28 1990-05-14 Ortho Pharma Corp IMMUNE SUPPRESSIVE PEPTIDES AND METHOD FOR THEIR USE.
FR2622700B1 (fr) * 1987-10-30 1993-08-13 Aderegem Proteine et ses fragments representant l'expression specifique du gene ps2 des cancers du sein, anticorps obtenus a partir de ladite proteine et/ou de ses fragments, leurs applications a la detection et au diagnostic de cancers du sein
EP0341603A3 (en) 1988-05-09 1990-07-04 Abbott Laboratories Atrial peptide derivatives
US5223485A (en) 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
IL98310A (en) * 1990-06-08 1996-08-04 Astra Ab Medicinal preparations containing a history of cystine
AU655599B2 (en) 1990-09-11 1995-01-05 Institute For Child Health Research Cloning and sequencing of allergens of dermatophagoides (house dust mite)
WO1993000108A1 (en) 1991-06-28 1993-01-07 Corvas International, Inc. Novel inhibitors of platelet aggregation
KR100260342B1 (ko) 1991-10-16 2000-07-01 스타세이 엘. 첸링 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
IL106214A (en) 1993-07-01 1998-12-06 Yeda Res & Dev Thf-gamma2 analogs and pharmaceutical compositions comprising them
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
WO1996001318A1 (en) 1994-07-05 1996-01-18 Steeno Research Group A/S Immunomodulators
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides

Also Published As

Publication number Publication date
EE9600208A (et) 1997-06-16
AU5166296A (en) 1996-10-16
IS4382A (is) 1996-11-08
PL317348A1 (en) 1997-04-01
NO964959L (no) 1996-11-21
EP0785945A1 (en) 1997-07-30
JPH10501003A (ja) 1998-01-27
HU9603537D0 (en) 1997-02-28
NO964959D0 (no) 1996-11-21
US6228373B1 (en) 2001-05-08
HUP9603537A2 (en) 1997-08-28
IL117615A0 (en) 1996-07-23
HUP9603537A3 (en) 1998-03-02
SK150196A3 (en) 1997-06-04
NZ304468A (en) 1999-02-25
AR002724A1 (es) 1998-04-29
BR9605890A (pt) 1997-09-23
ZA962345B (en) 1996-09-25
CZ344096A3 (en) 1997-05-14
CA2189656A1 (en) 1996-10-03
TR199600932T1 (tr) 1997-03-21
WO1996030397A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
FI905602L (fi) Fullfaergs tredimensionell projektionsdisplay.
DE122005000024I1 (de) Darifenacin enthaltende Pharmazeutische Zubereitungen.
HN1996000124A (es) 2-ox y 2- tio - 1, 2 dihidroquinolinil oxazolidinonas
ATE360032T1 (de) Cystein-reiche rezeptoren-train
IT1312366B1 (it) Resina copolimerica, sua preparazione e photoresist che la utilizza.
DE69023445D1 (de) Projektionssystem.
DE69109321D1 (de) Anzeigevorrichtung mit aktiver Matrix.
DE69114734D1 (de) Backenbrecher.
DE69111930D1 (de) Künstlicher Antikörper.
DE59100757D1 (de) Zweistufige Kryopumpe.
DE68909641D1 (de) Projektionsdarstellungsgerät.
SE9501067D0 (sv) New peptides
TR199500915A2 (tr) Peptidler.
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
IT8821556A0 (it) Peptidi immunostimolanti.
DE69028783D1 (de) Künstliche peptide, die die zellbindung steigern
ZA969402B (en) Novel oligopeptides, the preparation and use thereof.
DE68918290D1 (de) Taumelscheibenkompressor.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
TR199601012A2 (tr) Sampuan terkibi.
DE69102671D1 (de) Taumelscheibenverdichter.
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
MX9605651A (es) Nuevos peptidos con efectos inmunorreguladores.
DE69629256D1 (de) Polymerzusammensetzung mit niedrigem Druckverformungsrest